AMD Drug Study Sparks Concerns
(MedPage Today) -- The study that put bevacizumab (Avastin) and ranibizumab (Lucentis) into a dead heat for treating "wet" age-related macular degeneration did not assure that the pricier drug would be out of contention or that the lower-cost one is a winner.